Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PhoenixBio Co's Revenue for the
three
months ended in Mar. 2026 was 円365 Mil. PhoenixBio Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was 円167 Mil.
Hence, PhoenixBio Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.19.
PhoenixBio Co (TSE:6190) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PhoenixBio Co Receivables Turnover Related Terms
PhoenixBio Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6190 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, PhoenixBio Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a Receivables Turnover of 2.19 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PhoenixBio Co and its competitors. According to the industry distribution chart, PhoenixBio Co ranks #243 out of 842 companies in the Biotechnology industry, placing it in the top 28.9%.
Is PhoenixBio Co's Receivables Turnover too high?
PhoenixBio Co's current Receivables Turnover is 2.19. The Biotechnology industry median Receivables Turnover is 5.27. PhoenixBio Co's value of 2.19 is 58.4% below this industry median. Based on the distribution chart, PhoenixBio Co ranks #243 out of 842 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PhoenixBio Co has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #243 out of 842 companies for Receivables Turnover. This puts PhoenixBio Co in the upper half of its industry. The industry median Receivables Turnover is 5.27. PhoenixBio Co's value of 2.19 is 58.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhoenixBio Co's current Receivables Turnover of 2.19 is 58.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PhoenixBio Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhoenixBio Co's current Receivables Turnover is 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円364.78, compared to a current price of 円343.00 — trading 6% below its estimated fair value. The current Receivables Turnover is 2.19 and 58.4% below the Biotechnology industry median of 5.27. PhoenixBio Co's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Receivables Turnover is 2.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円343.00 is trading 6% below its estimated GF Value™ of 円364.78.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
Receivables Turnover: 2.19
GF Value™: 円364.78 vs. price of 円343.00 (6% below fair value)
Industry Position: 58.4% below the Biotechnology median (#243 of 842)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
54GF Score
Get the complete analysis for TSE:6190
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
